Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67

Human Pathology

Volumn 28, Issue 8, 1997, Pages 974-979

  Mack, Lloyd ^a   Kerkvliet, Nancy ^a   Doig, Gordon ^a   O'Malley, Frances P ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Biological markers; Classification; Ductal carcinoma in situ

Indexed keywords

KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; TUMOR VOLUME;

EID: 0030810732     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90014-9     Document Type: Article

References (22)

1. Lagios MD, Margolin FR, Westdahl PR, et al: Mammographically detected duct carcinoma in situ: Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63:618-624, 1989
2. van Dongen JA, Holland R, Peterse JL, et al: Ductal carcinoma in-situ of the breast: Second EORTC consensus meeting. EurJ Cancer Clin Oncol 28:626-629, 1992
3. Lagios M: Duct carcinoma in situ: Pathology and treatment. Surg Clin North Am 70:853-871, 1990
4. Silverstein MJ, Poller DN, Walsman JR, et al: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154-1157, 1995
5. Holland R, Peterse JL, Millis RR, et al: Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 11:167-180, 1994
6. Bellamy COC, McDonald C, Salter DM, et al: Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. HUM PATHOL 24:16-23, 1993
7. Ottesen GL, Graversen HP, Blichert-Toft M, et al: Ductal carcinoma in situ of the female breast. Am J Surg Pathol 16:1183-1196, 1992
8. Scott M, Axelsson K, Lagios MD, et al: Ductal carcinoma in situ of the breast, reproducibility of histologic subtype analysis. Modern Pathol 125:8, 1995
9. Bobrow LG, Happerfield LC, Gregory WM, et al: The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199-207, 1994
10. Zafrani B, Leroyer A, Fourquet A, et al: Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification: A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erB-2 proteins, and proliferative activity. Semin Diagn Pathol 11:208-214, 1994
11. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalinfixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
12. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
13. SAS Institute I: In SAS Users Guide: Statistics Version 6. Gary, NC, 1990
14. Lagios MD, Westdahl PR, Margolin FR, et al: Ductal carcinoma in situ: Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failures. Cancer 50:1309-1314, 1982
15. Poller D, Silverstein M, Galea M, et al: Ductal carcinoma in situ of the breast: A proposal for a new simplified histological classification, association between cellular proliferation and c-erb B2 protein expression. Mod Pathol 7:257-262, 1994
16. Patchefsky AS, Schwartz GF, Finkelstein SD, et al: Heterogeneity of intraductal carcinoma of the breast. Cancer 63:731-741, 1989
17. O'Malley FP, Page DL, Nelson EH, et al: Ductal carcinoma in situ of the breast with apocrine cytology: Definition of a borderline category. HUM PATHOL 25:164-168, 1994
18. Leal CB, Schmitt FC, Bento MJ, et al: Ductal carcinoma in situ: Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erbB-2 protein. Cancer 75:2123-2131, 1995
19. O'Malley FP, Vnencak-Jones CL, Dupont WD, et al: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Lab Invest 71:67-72, 1994
20. Walker RA, Dearing SJ, Lane DP, et al: Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165:203-211, 1991
21. Poller DN, Roberts EC, Bell JA, et al: p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. HUM PATHOL 24:463-468, 1993
22. Siziopikou KP, Prioleau JE, Harris JR, et al: bcl-2 Expression in the spectrum of preinvasive breast lesions. Cancer 77:499-506, 1996